免疫查核点抑制剂市场规模、份额及成长分析（按类型、应用、通路和地区）- 2025-2032 年产业预测

2023 年全球免疫查核点抑制剂市场规模价值为 484.7 亿美元，预计将从 2024 年的 568.1 亿美元成长到 2032 年的 2022.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 17.2%。

肺癌、乳癌、膀胱癌和子宫颈癌以及黑色素瘤和何杰金氏淋巴瘤等各种癌症的发生率不断上升，推动了免疫查核点抑制剂的采用。根据加拿大癌症协会统计，大约 40% 的加拿大人在其一生中会被诊断出患有癌症，并且死于癌症的风险很高，因此对有效的诊断和治疗解决方案的需求日益增长。特别是随着新型免疫查核点抑制剂研究的进展，市场正呈现扩张的迹象。尤其是FDA核准基于遗传肿瘤特征的Pembrolizumab ，凸显了标靶治疗的进展。儘管面临技术进步和社会意识增强等挑战，免疫查核点抑制剂市场仍显示出强劲的成长潜力，尤其是在新兴国家，为相关人员带来了光明的前景。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局
• 专利分析

免疫查核点抑制剂市场规模（按类型）

• 市场概况
• PD-1 抑制剂
• PD-L1 抑制剂
• CTLA-4 抑制剂
• 其他的

免疫查核点抑制剂市场规模（按应用）

• 市场概况
• 肺癌
• 乳癌
• 恶性黑色素瘤
• 膀胱癌
• 何杰金氏淋巴瘤
• 其他的

免疫查核点抑制剂市场规模（按分销管道）

• 市场概况
• 医院药房
• 零售药局
• 网路药局

免疫查核点抑制剂市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Bristol-Myers Squibb Company（USA）
• Merck & Co., Inc.（USA）
• F. Hoffmann-La Roche AG（Switzerland）
• Regeneron Pharmaceuticals, Inc.（USA）
• AstraZeneca PLC（UK）
• Eli Lilly and Company（USA）
• Sanofi（France）
• BeiGene Ltd.（China）
• Shanghai Junshi Biosciences Ltd.（China）
• GlaxoSmithKline PLC（UK）
• Immutep Ltd.（Australia）
• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Genentech, Inc.（USA）
• Incyte Corporation（USA）
• MacroGenics, Inc.（USA）
• Agenus Inc.（USA）
• Jiangsu Hengrui Medicine Co., Ltd.（China）
• Innovent Biologics, Inc.（China）
• Daiichi Sankyo Company, Limited（Japan）

结论和建议

Global Immune Checkpoint Inhibitors Market size was valued at USD 48.47 billion in 2023 and is poised to grow from USD 56.81 billion in 2024 to USD 202.22 billion by 2032, growing at a CAGR of 17.2% during the forecast period (2025-2032).

The rising incidence of various cancers, including lung, breast, bladder, and cervical cancers, alongside melanomas and Hodgkin lymphoma, is driving the adoption of immune checkpoint inhibitors. According to the Canadian Cancer Society, approximately 40% of Canadians will receive a cancer diagnosis in their lifetime, with a significant mortality risk, fueling the demand for effective diagnostic and therapeutic solutions. The market is set for expansion, particularly with ongoing research into novel immune checkpoint inhibitors. Notably, pembrolizumab's FDA approval, based on genetic tumor features, highlights progress in targeted treatments. While challenges persist, including technological advancements and increased public awareness, the immune checkpoint inhibitors market demonstrates robust growth potential, especially in emerging economies, indicating a promising outlook for stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immune Checkpoint Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immune Checkpoint Inhibitors Market Segments Analysis

Global Immune Checkpoint Inhibitors Market is segmented by Type, Application, Distribution Channel and region. Based on Type, the market is segmented into PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors and Others. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Melanoma, Bladder Cancer, Hodgkin Lymphoma and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Immune Checkpoint Inhibitors Market

The global immune checkpoint inhibitors market has experienced substantial growth driven by technological innovations and scientific advancements in the field of immunotherapy. In recent years, extensive research has highlighted the essential function of the immune system in fighting cancer, resulting in the creation of therapies that bolster the body's natural immune response to neoplastic cells. As a result, immune checkpoint inhibitors have become a fundamental component of contemporary cancer treatment, specifically targeting and modulating proteins that control immune checkpoints. This evolution in cancer therapy is revolutionizing patient outcomes and expanding the potential for novel treatment options across various malignancies.

Restraints in the Global Immune Checkpoint Inhibitors Market

A major constraint impacting the global immune checkpoint inhibitors market is the steep cost of these therapies. Treatments like pembrolizumab (Keytruda) and nivolumab (Opdivo) carry high price tags due to the extensive investment in research and development, intricate manufacturing methods, and the exorbitant expenses associated with clinical trials. Consequently, a single treatment regimen can amount to tens of thousands of dollars, rendering it unaffordable for numerous patients and healthcare systems, particularly in low- and middle-income nations. This financial burden significantly hampers accessibility to these potentially life-saving therapies for a large segment of the population.

Market Trends of the Global Immune Checkpoint Inhibitors Market

The global immune checkpoint inhibitors market is witnessing significant growth, primarily driven by the rising incidence of cancer, which remains a major health challenge worldwide. As cancer rates continue to surge due to factors such as aging populations and lifestyle changes, the demand for innovative therapies is escalating. Immune checkpoint inhibitors, which have shown promising results in enhancing the immune response against tumors, are becoming essential in oncology treatment regimens. This upward trend is further fueled by ongoing research, the development of novel therapies, and expanding applications in various cancer types, positioning the market for robust expansion in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Immune Checkpoint Inhibitors Market Size by Type & CAGR (2025-2032)

• Market Overview
• PD-1 Inhibitors
• PD-L1 Inhibitors
• CTLA-4 Inhibitors
• Others

Global Immune Checkpoint Inhibitors Market Size by Application & CAGR (2025-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Melanoma
• Bladder Cancer
• Hodgkin Lymphoma
• Others

Global Immune Checkpoint Inhibitors Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Immune Checkpoint Inhibitors Market Size & CAGR (2025-2032)

• North America (Type, Application, Distribution Channel)
  • US
  • Canada
• Europe (Type, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Junshi Biosciences Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immutep Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agenus Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Hengrui Medicine Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovent Biologics, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations